<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814645</url>
  </required_header>
  <id_info>
    <org_study_id>AIR001 CS02</org_study_id>
    <nct_id>NCT00814645</nct_id>
  </id_info>
  <brief_title>Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers</brief_title>
  <acronym>AIR001-CS02</acronym>
  <official_title>A Placebo-Controlled, Phase 1b, Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution (AIR001 INHALATION SOLUTION) in Normal, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aires Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aires Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety and tolerability of AIR001 Inhalation
      Solution when administered under conditions of hypoxia and to identify dose levels of drug
      resulting in a reduction in pulmonary arterial pressure under these hypoxic conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The measurement of pulmonary arterial pressures by echocardiography.</measure>
    <time_frame>Pretreatment and up to 2 hours post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics</measure>
    <time_frame>Pretreatment to 8 hours post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology, blood chemistry, coagulation and urinalysis, methemoglobin, oxygen saturation, electrocardiogram, troponin, and vital signs and adverse events.</measure>
    <time_frame>Pretreatment, post treatment, and 24 hours post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrite Inhalation Solution</intervention_name>
    <description>a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <other_name>AIR001 Inhalation Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and AIR001 Inhalation Solution (Expansion arm)</intervention_name>
    <description>On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.</description>
    <arm_group_label>Expansion arm</arm_group_label>
    <other_name>AIR001 Inhalation Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal male and female volunteers

          -  Age 18-55

          -  Demonstrate a rise in pulmonary artery pressure to low inspired oxygen concentration
             (a normal response to breathing a low level of oxygen)

        Exclusion Criteria:

          -  Significant medical illnesses

          -  Risk factors for pulmonary hypertension

          -  G6PD or Cytochrome B5 Reductase deficiencies

          -  History of any form of altitude sickness

          -  Current prescription or over the counter medication use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne K Swan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

